First-in-human evaluation of CDR404, a MAGE-A4–targeted T cell engager, in ovarian cancer: Initial pharmacodynamic and clinical activity

CDR404 - CDR-Life

https://oncologypro.esmo.org/congress-resources/esmo-immuno-oncology-congress-2025?presentation=first_in_human_evaluation_of_cdr404__a_mage_a4_tar

K.S. Rohrberg1; M. Morotti2; G. Curigliano3; R. Leidner4; M. Diamond5; N. Vachtsevanou6; C. Leisner7; S. Holland6; L. Borras6; D. Lenherr-Frey8; M. Vrohlings6; S. Biswas6

Oct 27, 2025